We are live on ! Find out more
AAP

Ardsley Advisory Partners Portfolio holdings

AUM $960M
1-Year Est. Return 207.76%
This Fund
S&P 500
This Quarter Est. Return
-19.38%
1 Year Est. Return
+207.76%
3 Year Est. Return
+554.53%
5 Year Est. Return
+728.66%
10 Year Est. Return
+4,084.52%
AUM
$398M
AUM Growth
-$344M
Cap. Flow
-$248M
Cap. Flow %
-62.23%
Top 10 Hldgs %
44.07%
Holding
188
New
36
Increased
27
Reduced
23
Closed
84

Top Buys

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$14.6M
2
CELG
Celgene Corp
CELG
+$10.8M
3
TLND
Talend S.A. American Depositary Shares
TLND
+$9.74M
4
AQUA
Evoqua Water Technologies Corp. Common Stock
AQUA
+$9.08M
5
ZEN
ZENDESK INC
ZEN
+$8.55M

Top Sells

Rank Stock Value
1
MPC icon
Marathon Petroleum
MPC
+$27M
2
KNX icon
Knight Transportation
KNX
+$17.2M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$15.8M
4
MGY icon
Magnolia Oil & Gas
MGY
+$14.6M
5
ADMS
Adamas Pharmaceuticals
ADMS
+$10.2M

Sector Composition

Rank Sector Weight
1 Technology 30.17%
2 Healthcare 20.63%
3 Industrials 11.87%
4 Utilities 10.14%
5 Consumer Staples 5.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABT icon
76
Abbott
ABT
$187B
$361K 0.09%
+5,000
New +$351K
OPCH icon
77
Option Care Health
OPCH
$3.53B
$357K 0.09%
25,000
+6,250
+33% +$82.4K
TWTR
78
DELISTED
Twitter, Inc.
TWTR
$345K 0.09%
+12,000
New +$376K
LITE icon
79
Lumentum
LITE
$50.7B
$336K 0.08%
8,000
-117,000
-94% -$5.76M
VRTX icon
80
Vertex Pharmaceuticals
VRTX
$124B
$331K 0.08%
2,000
-4,000
-67% -$693K
XBI icon
81
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$323K 0.08%
4,500
-2,500
-36% -$201K
CBAY
82
DELISTED
Cymabay Therapeutics
CBAY
$315K 0.08%
40,000
-10,000
-20% -$95.2K
EHC icon
83
Encompass Health
EHC
$11.5B
$309K 0.08%
+6,285
New +$357K
REZI icon
84
Resideo Technologies
REZI
$5.55B
$308K 0.08%
+15,000
New +$320K
GWPH
85
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$292K 0.07%
+3,000
New +$394K
DBX icon
86
Dropbox
DBX
$7.48B
$286K 0.07%
+14,000
New +$323K
AZRE
87
DELISTED
Azure Power Global Limited
AZRE
$253K 0.06%
+27,500
New +$306K
ALBO
88
DELISTED
Albireo Pharma Inc
ALBO
$248K 0.06%
10,100
– –
MGNI icon
89
Magnite
MGNI
$2.82B
$242K 0.06%
+65,000
New +$248K
GRDX
90
GridAI Technologies Corp
GRDX
$21M
$182K 0.05%
1
– –
APEN
91
DELISTED
Apollo Endosurgery, Inc.
APEN
$167K 0.04%
48,377
-1,623
-3% -$8.01K
CHRS icon
92
Coherus Oncology
CHRS
$222M
$136K 0.03%
15,000
– –
ABEO icon
93
Abeona Therapeutics
ABEO
$343M
$134K 0.03%
749
-651
-47% -$142K
GSM icon
94
CALL
FerroAtlántica
GSM
$628M
– –
0
– –
ADMA icon
95
ADMA Biologics
ADMA
$2.04B
$120K 0.03%
50,000
-50,000
-50% -$248K
HTGM
96
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$89K 0.02%
194
– –
LITS
97
Lite Strategy Inc
LITS
$33M
$85K 0.02%
1,603
-897
-36% -$55.3K
CGRN
98
DELISTED
Capstone Green Energy Corporation Common Stock
CGRN
$75K 0.02%
12,500
+10,500
+525% +$82.6K
CSCI
99
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
$74K 0.02%
+250
New +$59.8K
NEPT
100
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$64K 0.02%
18
– –
2 3
4
5 6

Similar funds

NA
Navellier & Associates Reno, Nevada $960M AUM 79.37% 1-Year Est. Return
MK
MASTERINVEST Kapitalanlage Vienna $962M AUM 27.59% 1-Year Est. Return
QIM
Quantitative Investment Management Charlottesville, Virginia $963M AUM 12.95% 1-Year Est. Return
JVBC
J.V. Bruni & Co Colorado Springs, Colorado $958M AUM 22.2% 1-Year Est. Return
TFP
Triple Frond Partners San Francisco, California $963M AUM 27.45% 1-Year Est. Return
UWPG
Ullmann Wealth Partners Group Jacksonville Beach, Florida $963M AUM 17.06% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
PHS
Pekin Hardy Strauss Chicago, Illinois $957M AUM 44.61% 1-Year Est. Return

Ardsley Advisory Partners's Q4 2018 Portfolio in Review

As of Q4 2018, Ardsley Advisory Partners held 188 positions worth $398M, down 46% from $742M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Ardsley Advisory Partners withdrew a net $248M in Q4 2018, closing 84 positions and reducing 23 holdings. Its most notable exit was Marathon Petroleum, an estimated $27M position sold in full.

By sector, the portfolio is most concentrated in Technology at 30% of assets, up from 16% a quarter earlier, followed by Healthcare and Industrials.

Against the trend, Ardsley Advisory Partners opened a new position in CVS Health worth $12.8M.

  • Ardsley Advisory Partners's largest Q4 2018 buy was CVS Health: 195,000 shares worth $12.8M.
  • Ardsley Advisory Partners added most to Celgene Corp in Q4 2018, an estimated $10.8M increase.
  • Ardsley Advisory Partners's biggest Q4 2018 reduction was Progenics Pharmaceuticals Inc, cutting an estimated $7.73M.
  • Ardsley Advisory Partners fully exited Marathon Petroleum in Q4 2018, selling an estimated $27M.
  • Ardsley Advisory Partners's ten largest holdings make up 44% of its $398M portfolio in Q4 2018.
  • Ardsley Advisory Partners opened 36 new positions and closed 84 in Q4 2018.
  • Ardsley Advisory Partners's portfolio value fell 46% quarter-over-quarter to $398M.

Based on Ardsley Advisory Partners's 13F filing for Q4 2018, filed 14 Feb 2019.